

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/800,022	
Filing Date	March 12, 2004	
First Named Inventor	Frederick F. VanGoor	
Group Art Unit	1614 626	
Examiner Name	Not Yet Assigned Joseph Kosa	ck
Attorney Docket Number	VPI/03-103 US	

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
						Y	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
JK	B1	wo	00/07996	Chiron Corporation	17 February 2000	
JΚ	B2	wo	03/084544	CV Therapeutics, Inc.	16 October 2003	
JK	В3	DE	41 26 543	Chem. & Pharm. Patent Hold Ltd.	11 February 1993	
JK	B4	FR	2.104.932	Ferlux	28 April 1972	

OTHER NON PATENT LITERATURE DOCUMENTS				
Exam Cite Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
JΚ	CI	Nargund, et al., "Synthesis and Anti-inflammatory Activity of Fluorinated Phenyl Styryl Ketones and N-Phenyl-5-substituted Aryl-3-p-(fluorophenyl) Pyrazolins and Pyrazoles", Journal of Pharm. Sciences, Am. Pharm. Association, Vol 81, No. 9, Pages 892-894, Sept. 1992.		
しと	C2	Nair, et al. "Synthesis & Reactions of 1-(2-Furyl)-3-(substituted-2-hydroxyphenyl)propanediones", Indian J. Chem., Vol. 21, Pages 573-574, 1982		
JK	C3	Database Chemcats, Zelinski Inst. Of Organic Chemistry, Moscow, XP-002288253, 2003		
	1			

* a copy of this reference is not provided	l as it was previously cited by or submitted to the office in a prior application,
U.S.S.N, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,
continuation-in-part, and divisional appli	ications).

Examiner Signature	Kosack	Date Considered	2-10-0Ce
-----------------------	--------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.